Delivery Order SPE2DB22D2206-SPE2DB25FJK97
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Lupron Depot 11.25 mg 3-month kits, valued at $33,612.02. This firm fixed-price delivery order, with an ultimate completion date of August 12, 2025, represents a competitively awarded, non-set-aside procurement with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 30, 2025, for the supply of Lupron Depot 11.25 mg three-month kits, valued at $34,676.08. This non-set-aside, competitively awarded contract employs firm fixed pricing and is scheduled for completion by May 1, 2025. AmerisourceBergen will perform this work from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a leading pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $13,483.53 to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Lupron Depot 11.25 mg 3-month kits, with completion targeted for September 15, 2025. This competitively awarded, firm fixed-price delivery order is being performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement supporting military and federal healthcare systems through...
- The Defense Logistics Agency awarded a $2,750.55 delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Lupron Depot 11.25 mg 3-month kits. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 3, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a task order issued under...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for Lupron Depot 11.25 mg 3-month kits valued at $7,855.98 under a firm fixed-price contract. This non-set-aside delivery order is scheduled for completion by August 11, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement through the company's existing...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Lupron Depot 11.25 mg 3-month kits valued at $29,864.38. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award through open competition. The contract is due for completion by July 30, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency Medical Supply Chain awarded a $42,779.28 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Lupron Depot 11.25 mg 3-month kits, with final delivery required by July 31, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $8,949.64 to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Lupron Depot 11.25 mg 3-month kits. This is a firm fixed price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of July 15, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Lupron Depot 11.25 mg 3-month kits, valued at $3,344.81. This delivery order is issued under a firm fixed-price contract type with no set-aside designation, indicating competitive award. The product will be delivered to the contractor's location in Conshohocken, Pennsylvania, with an ultimate completion date of September 8, 2025. This delivery order represents a...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order valued at $20,048.58 to AmerisourceBergen Drug Corp for Lupron Depot 3.75 mg kits. This is a firm fixed-price, competitively awarded delivery order with an ultimate completion date of September 12, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with the Defense Logistics Agency Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026,...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJK97Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Lupron Depot 11.25 mg 3-month kits with a ceiling value of $11,281.85. This firm fixed-price delivery order, which is not set-aside, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 billion through December 2026. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 15, 2025. This award reflects AmerisourceBergen Drug Corp's established role as a primary pharmaceutical vendor supporting federal military and healthcare procurement needs. As a major pharmaceutical distributor, AmerisourceBergen supplies a comprehensive range of medical products to the Defense Health Agency and other government healthcare systems through its global pharmaceutical support vehicle. The delivery order for Lupron Depot, a hormone treatment medication, is consistent with the company's extensive portfolio of competitively awarded contracts covering specialty medications, brand-name and generic pharmaceuticals, and specialized medical supplies across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.3k | 8/14/25 |